As the world's largest voluntary health agency dedicated to fighting blood cancers, The Leukemia & Lymphoma Society (LLS) is leading the offensive to dramatically improve outcomes for patients with acute myeloid leukemia (AML), one of the most lethal blood cancers.
LLS began funding AML research at our inception more than 66 years ago, and about 26 percent of our annual research budget goes to AML research. In the past five years alone we have invested nearly $100 million in AML research, with a focus on understanding the underlying causes of the disease to develop better therapies and save more lives.
LLS had the vision to make a “down payment” for patients with AML in 2009 by partnering with Celator Pharmaceuticals to advance CPX-351, an innovative formulation of two existing therapies, which recently outperformed standard therapy in a Phase 3 clinical trial for patients with secondary AML, a high-risk subset of the disease. This investment has the potential to pay off significantly as the first new treatment in 40 years for patients diagnosed with AML.
Through our Beat AML initiative, LLS is fostering collaboration among researchers at multiple institutions, regulators, pharmaceutical and biotechnology companies, primary healthcare physicians and patients, to develop effective, individualized therapies to treat patients with AML.
There are currently more than 100 therapeutic agents being studied for AML, which remains one of the most lethal blood cancers. Key areas of research are focused on targeting the different mechanisms that cause the disease, and among these are stem cell research, studying the cancer microenvironment, and harnessing the immune system.